An activation mechanism for an aerosol dispenser is presented having a first housing structure, an actuation member movably arranged in the first housing structure, wherein the first housing structure is provided with an actuation member opening in level with the axial position of the actuation member, and an activation member slidably attached to the first housing structure, the activation member slides between a non-triggering position and a triggering position relative to the first housing structure, wherein the activation member has a radially flexible tab portion that is offset from the actuation member opening when the activation member is in the non-triggering position, restricting radial flexing of the tab portion, and wherein the tab portion aligns with the actuation member opening when the activation member is in the triggering position, thereby enabling the tab portion to flex radially inwards to cause movement of the actuation member.

A nebulizer includes an insertable container and a counter device for counting operations of the nebulizer. The nebulizer can be opened for replacing the container. The counter devices blocks opening of the nebulizer until a predetermined number for operations has been reached.

Dispenser cap arrangements for enclosing a portion of a dispenser of a medicament are described herein.

The present invention provides an inhaler comprising a housing which contains a blister strip having a plurality of blisters which contain powdered medicament for inhalation; a mouthpiece through which the medicament is inhaled by a user; an indexing wheel for indexing the blister strip; an opening mechanism for opening the blisters; an actuator which is movable between a first position and a second position in order to operate the indexing wheel and the opening mechanism; and a coupling mechanism for coupling the actuator to the indexing wheel so that the indexing wheel rotates together with the actuator during part of the motion of the actuator; characterized in that the coupling mechanism comprises a shuttle that rotates on the same axis as, and translates axially relative to, the indexing wheel.

An inhaler includes a main body having a canister housing, a medicament canister retained in a central outlet port of the canister housing, and a dose counter having an actuation member for operation by movement of the medicament canister. The canister housing has an inner wall, and a first inner wall canister support formation extending inwardly from a main surface of the inner wall. The canister housing has a longitudinal axis X which passes through the center of the central outlet port. The first inner wall canister support formation, the actuation member, and the central outlet port lie in a common plane coincident with the longitudinal axis X such that the first inner wall canister support formation protects against unwanted actuation of the dose counter by reducing rocking of the medicament canister relative to the main body of the inhaler.

The present invention relates to a liquid pharmaceutical preparation and a method for administering the pharmaceutical preparation by nebulizing the pharmaceutical preparation in an inhaler. The propellant-free pharmaceutical preparation comprises: (a) glycopyrrolate and indacaterol maleate; (b) a solvent; (c) a pharmacologically acceptable solubilizing agent; (d) a pharmacologically acceptable preservative, (e) a pharmacologically acceptable stabilizer.

Provided is a system (10) for determining a probability of a CORD exacerbation in a subject. The system comprises a first inhaler (100) for delivering a rescue medicament to the subject. The rescue medicament may be suitable for treating the subject's acute respiratory disease, for example by effecting rapid dilation of the bronchi and bronchioles upon inhalation of the medicament. The first inhaler has a use-detection system (12B) configured to determine a rescue inhalation performed by the subject using the first inhaler. The system optionally includes a second inhaler for delivering a maintenance medicament to the subject during a routine inhalation A sensor system (12A) is configured to measure a parameter relating to airflow during the rescue inhalation and/or during the routine inhalation, when the second inhaler is included in the system. The system further comprises a processor (14) configured to determine a number of the rescue inhalations during a first time period, and receive the parameter measured for at least some of the rescue and/or routine inhalations. The processor then determines, using a weighted model, the probability of the CORD exacerbation based on the number of rescue inhalations and the parameters. The model is weighted such that the parameters are more significant in the probability determination than the number of rescue inhalations. Further provided is a method for determining the probability of a COPD exacerbation in a subject, which method employs the weighted model.

Various exemplary drug delivery devices with on-board drug destruction, drug products utilizing the same, and methods of using drug delivery devices with on-board drug destruction are provided. In general, a nasal drug delivery device configured to dispense a drug therefrom into a nose includes a destruction mechanism configured to destroy drug contained in the drug delivery device. The destruction mechanism can be configured to destroy the drug before a first actuation of the drug delivery device to deliver the drug therefrom such that the destruction mechanism destroys substantially all of the drug contained in the drug delivery device. Alternatively or in addition, the destruction mechanism can be configured to destroy the drug after a first actuation of the drug delivery device to deliver the drug therefrom such that the destruction mechanism destroys substantially all of the drug remaining in the drug delivery device.

The invention relates to a device comprising a body (10), a reservoir (100) mounted in an axially slidable manner relative to said body (10), a metering valve (200) assembled on said reservoir (100), said device comprising: —a blocking element (500), —a triggering element (600), —a triggering system controlled by inhalation (60) cooperating with said triggering element (600), and —an actuating member (800) cooperating with said blocking element (500), said device comprising an automatic valve release system which automatically returns said valve (210) of said valve (200) to its rest position after actuation of the valve regardless of the position of said actuating member (800).

A nasal drug delivery device for delivering a plume derived from a propellant and a drug compound. The drug compound is in an intranasal dosage form in the form of powder, suspension, dispersion, or liquid. The propelled intranasal dosage form is deposited within the upper nasal cavity such as the olfactory region. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing channel where the intranasal dosage form is aerosolized. The aerosolized intranasal dosage form passes through a nozzle thus delivering a plume to the user's upper nasal cavity.